What is Breast Cancer?

Breast cancer is a malignant neoplasm that develops from the epithelial cells of the mammary ducts or lobules of the breast. It is the most common malignancy in women worldwide and a significant cause of morbidity.

Despite its frequency, the prognosis of the disease has improved dramatically in recent decades. The systematic implementation of preventive screening, the evolution of surgical techniques, the development of modern systemic therapies, and the establishment of personalized oncological approaches have substantially contributed to reducing mortality.

Today, when breast cancer is diagnosed at an early stage, cure rates are remarkably high and therapeutic interventions are often less burdensome.

How does it develop?

Breast cancer is not a single disease, but a heterogeneous group of neoplasms with different morphological, molecular, and clinical characteristics. Its biological behavior can vary significantly from patient to patient.

The most common histological types are invasive ductal carcinoma and invasive lobular carcinoma. Both types originate from normal breast cells that, through the accumulation of genetic and molecular alterations, acquire uncontrolled capacity for proliferation and invasion of surrounding tissues.

Modern oncology is not limited to histological diagnosis alone. The biological identity of the tumor is determined by specific molecular markers, such as:

expression of hormone receptors (estrogen and progesterone),
overexpression or absence of HER2,
grade of differentiation,
proliferation index (Ki-67).

Based on these characteristics, tumors are classified into molecular subtypes (such as hormone receptor-positive, HER2-positive, or triple-negative), allowing the selection of targeted and personalized therapeutic strategies.

The Importance of Personalization

A diagnosis of breast cancer no longer implies a single treatment regimen for all women. Instead, each case is evaluated individually, taking into account the stage of the disease, the biological characteristics of the tumor, the patient’s age, and comorbidities.

The modern approach is based on multidisciplinary collaboration (breast surgeon, medical oncologist, radiation oncologist, pathologist, radiologist), with the goal of selecting the most appropriate and effective treatment.

What are the risk factors?

Breast cancer is a multifactorial disease. Factors that increase risk include:

advancing age,
first-degree family history,
genetic mutations (e.g., BRCA1/2),
early menarche or late menopause,
nulliparity or late first pregnancy,
postmenopausal obesity,
prolonged hormone therapy.

However, a significant proportion of women who are diagnosed have no identifiable risk factor.

What are the possible symptoms?

In early stages there may be no symptoms. Possible clinical signs include:

palpable mass,
change in breast shape or size,
nipple retraction,
skin thickening,
“peau d’orange” appearance,
bloody discharge,
palpable axillary lymph nodes.

The absence of symptoms does not exclude the presence of disease — this is why preventive screening is essential.

Staging

Staging is based on the TNM system and evaluates:

tumor size (T),
lymph node involvement (N),
presence of distant metastases (M).

The disease is classified into early breast cancer, locally advanced cancer, and metastatic cancer. Staging guides the treatment strategy.

What is the treatment approach?

Management is multifactorial and personalized. The treatment strategy is determined by the stage, the biological characteristics of the tumor, the patient’s age, general health status, and preferences.

Surgical treatment — It is the primary pillar in early stages and may include: lumpectomy (breast conservation), mastectomy, sentinel lymph node biopsy or axillary lymph node dissection, and breast reconstruction.

Systemic therapy — It may include: chemotherapy, endocrine therapy, targeted therapies, and immunotherapy (in specific cases).

Radiation therapy — It is commonly used after breast-conserving surgery or in specific cases after mastectomy.

Prognosis

Prognosis depends on the stage at diagnosis, the biological characteristics, and the response to treatment. In early stages, five-year survival rates are exceptionally high.

Early diagnosis remains the most important prognostic factor.

The Modern Approach

Breast cancer today is not treated with a single, predetermined approach. The treatment paradigm has changed fundamentally in recent years, as advances in molecular biology and clinical research have enabled a better understanding of the heterogeneity of the disease.

Modern oncology is based on personalized therapy. Each tumor is evaluated according to its histological and molecular characteristics, the stage of the disease, and the individual circumstances of each woman. Treatment selection is not generic but tailored, aiming for maximum effectiveness with minimal burden.

A central role is played by multidisciplinary collaboration. The decision on the treatment plan is made within an organized team that includes a breast surgeon, medical oncologist, radiation oncologist, radiologist, and pathologist. This collective approach ensures comprehensive and evidence-based care.

At the same time, particular emphasis is placed on preserving quality of life. Modern surgical techniques are often conservative, systemic therapies are more targeted, and side effects are better managed compared to the past. Treatment is not only about curing the disease, but also about the physical and psychological well-being of the woman.

A diagnosis of breast cancer requires composure, organization, and scientific guidance. The initial shock is understandable; however, modern medicine offers more treatment options than ever before. With proper planning and a personalized strategy, the disease is effectively managed in the majority of cases.